307 Clinical College of PLA,Anhui Medical University,Hefei 230032,China (Tang MQ,Wu SHK);Department of Radiation Oncology (Tang MQ,Wu SHK,Sun B,Huang ZH,Zhao RG,Wang JL,Shen G),Department of Breast Cance (Song ST),307 Hospital of PLA,Beijing 100071,China
Abstract： Objective To evaluate the effects and significance of adjuvant radiotherapy after neoadjuvant chemotherapy on local recurrence (LR) rate in patients with stage T1-2N1M0 breast cancer. Methods Clinical data were collected from patients with stage T1-2N1M0 breast cancer who were admitted to our hospital and treated with neoadjuvant chemotherapy from 2005 to 2010. The clinical outcomes in those patients were analyzed after treatment with adjuvant radiotherapy. A total of 144 patients with a median age of 45 years (23-72 years) were enrolled as subjects. Results In the 144 patients, 30 patients (21%) who had pathological complete response (pCR) in primary breast tumor and axillary lymph node received adjuvant radiotherapy;10 out of 45 patients who had pCR in axillary lymph node alone did not receive adjuvant radiotherapy;6 out of 69 patients who still had axillary lymph node metastasis after treatment did not receive adjuvant radiotherapy;all of the rest received adjuvant radiotherapy. In all patients, the median follow-up time was 88 months;46 patients (32%) had relapse and metastasis. The 5-year LR rate was 3.0% in patients with pCR. In patients with pCR in axillary lymph node metastasis after neoadjuvant chemotherapy, there was no significant difference in the 5-year LR rate between patients treated with and without radiotherapy (7% vs. 16%,P=0.181). In patients with axillary lymph node metastasis after neoadjuvant chemotherapy, there was also no significant difference in the 5-year LR rate between patients treated with and without radiotherapy (15.9% vs. 33.3%,P=0.267). In all patients, those with pCR had significantly longer disease-free survival (DFS) time than those without pCR (P=0.017). Conclusions Patients with pCR to neoadjuvant chemotherapy have longer DFS time than those without pCR. The LR rate is relatively lower in patients with pCR undergoing adjuvant radiotherapy. Patients with pCR in axillary lymph node metastasis do not benefit from postoperative adjuvant radiotherapy. However, adjuvant radiotherapy is helpful in patients with axillary lymph metastasis after neoadjuvant chemotherapy who have high LR rates
Tang Mengqiu,Wu Shikai,Sun Bing et al. Disscussion and analysis of the effect of adjuvant radiotherapy after neoadjuvant chemotherapy for stage T1-2N1M0 breast cancer[J]. Chinese Journal of Radiation Oncology, 2016, 25(5): 472-476.
[1]Read RL,Flitcroft K,Snook KL,et al. Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer[J].ANZ J Surg,2015,85(5):315-320.DOI:10.1111/ans.12975. [2]Angelucci D,Tinari N,Grassadonia A,et al. Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice[J].J Cancer Res Clin Oncol,2013,139(2):269-280.DOI:10.1007/s00432-012-1325-9. [3]Rastogi P,Anderson SJ,Bear HD,et al. Preoperative chemotherapy:updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27[J].J Clin Oncol,2008,26(5):778-785.DOI:10.1200/JCO.2007.15.0235. [4]van der Hage JA,van de Velde CJH,Julien JP,et al. Preoperative chemotherapy in primary operable breast cancer:results from the european organization for research and treatment of cancer trial 10902[J].J Clin Oncol,2001,19(22):4224-4237. [5]Mamounas EP,Anderson SJ,Dignam JJ,et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy:results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27[J].J Clin Oncol,2012,30(32):3960-3966.DOI:10.1200/JCO.2011.40.8369. [6]Garg AK,Buchholz TA.Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer[J].Ann Surg Oncol,2015,22(5):1434-1440.DOI:10.1245/s10434-015-4402-x. [7]von Minckwitz G,Untch M,Blohmer JU,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J].J Clin Oncol,2012,30(15):1796-1804.DOI:10.1200/JCO.2011.38.8595. [8]Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials[J].Lancet,2005,366(9503):2087-2106.DOI:10.1016/S0140-6736(05)67887-7. [9]Overgaard M,Nielsen HM,Overgaard J.Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes,as recommended in international consensus reports？ A subgroup analysis of the DBCG 82 b&c randomized trials[J].Radiother Oncol,2007,82(3):247-253.DOI:10.1016/j.radonc.2007.02.001. [10]Garg AK,Strom EA,McNeese MD,et al. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage Ⅱ breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy[J].Int J Radiat Oncol Biol Phys,2004,59(1):138-145.DOI:10.1016/j.ijrobp.2003.10.037. [11]McGuire SE,Gonzalez-Angulo AM,Huang EH,et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy[J].Int J Radiat Oncol Biol Phys,2007,68(4):1004-1009.DOI:10.1016/j.ijrobp.2007.01.023. [12]Shim SJ,Park W,Huh SJ,et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage Ⅱ-Ⅲ breast cancer patients with pN0:a multicenter,retrospective study (KROG 12-05)[J].Int J Radiat Oncol Biol Phys,2014,88(1):65-72.DOI:10.1016/j.ijrobp.2013.09.021. [13]Le Scodan R, Selz J, Stevens D, et al:Radiotherapy for stage Ⅱ and stage Ⅲ breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys 82:e1-7, 2012.
2016, Vol. 25 
